Case 1:22-cv-00252-MSG Document 211-15 Filed 02/02/24 Page 1 of 8 PageID #: 14485
`Case 1:22-cv-00252-MSG Document 211-15 Filed 02/02/24 Page 1 of 8 PagelD #: 14485
`
`EXHIBIT K
`EXHIBIT K
`
`
`Case 1:22-cv-00252-MSG Document 211-15 Filed 02/02/24 Page 1 of 8 PagelD #: 14485
`
`EXHIBIT K
`EXHIBIT K
`
`
`
`Case 1:22-cv-00252-MSG Document 211-15 Filed 02/02/24 Page 2 of 8 PageID #: 14486
`
`IN THE UNITED STATES DISTRICT COURT
`
`FOR THE DISTRICT OF DELAWARE
`
`ARBUTUS BIOPHARMA CORPORATION
`and GENEVANT SCIENCES GmbH,
`
`
`
`
`Plaintiffs,
`
`v.
`
`
`
`
`
`)
`)
`)
`)
`)
`) C.A. No. 22-252-MSG
`)
`) HIGHLY CONFIDENTIAL –
`) OUTSIDE COUNSEL EYES ONLY
`)
`
`
`
`
`MODERNA, INC. and MODERNATX, INC.,
`
`
`
`
`Defendants.
`
`
`
`PLAINTIFF GENEVANT SCIENCES GMBH’S FIRST SUPPLEMENTAL RESPONSES
`AND OBJECTIONS TO DEFENDANTS MODERNA, INC. AND MODERNATX, INC.’S
`FIRST SET OF REQUESTS FOR ADMISSION (NOS. 5–8)
`
`Pursuant to Rules 26 and 36 of the Federal Rules of Civil Procedure and the applicable
`
`Local Rules of the U.S. District Court for the District of Delaware, Plaintiff Genevant Sciences
`
`GmbH (“Genevant”), by undersigned counsel, hereby objects and responds as follows to
`
`Defendants Moderna, Inc. and ModernaTX Inc.’s (collectively, “Moderna” or “Defendants”) First
`
`Set of Requests for Admission (Nos. 1–8).
`
`GENERAL OBJECTIONS & OBJECTIONS TO DEFINITIONS
`
`Genevant incorporates in their entirety the General Objections and Objections to
`
`Definitions provided in Plaintiffs’ Responses and Objections to Defendants Moderna, Inc. and
`
`ModernaTX Inc.’s First Requests for Production. These objections form a part of, and are hereby
`
`incorporated into, the response to each and every Request for Admission set forth below. Nothing
`
`in those responses, including any failure to recite a specific objection in response to a particular
`
`Request for Admission, should be construed as a waiver of any of these General Objections and
`
`Objections to Definitions.
`
`1
`
`
`
`Case 1:22-cv-00252-MSG Document 211-15 Filed 02/02/24 Page 3 of 8 PageID #: 14487
`
`DEFINITIONS
`
`Genevant incorporates in their entirety the Definitions provided in Plaintiffs’ Responses
`
`and Objections to Defendants Moderna, Inc. and ModernaTX Inc.’s First Requests for Production.
`
`These definitions form a part of, and are hereby incorporated into, the response to each and every
`
`Request for Admission set forth below.
`
`SPECIFIC OBJECTIONS AND RESPONSES
`
`
`
`
`
`
`
`
`
`
`
`
`
`2
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case 1:22-cv-00252-MSG Document 211-15 Filed 02/02/24 Page 4 of 8 PageID #: 14488
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`3
`
`
`
`
`
`
`
`
`
`Case 1:22-cv-00252-MSG Document 211-15 Filed 02/02/24 Page 5 of 8 PageID #: 14489
`
`
`
`
`
`
`
`REQUEST FOR ADMISSION NO. 7
`
`
`
`Admit that Roivant Sciences Ltd. is entitled to receive Litigation Proceeds should one or
`more Plaintiffs be awarded damages in This Action.
`
`RESPONSE TO REQUEST FOR ADMISSION NO. 7
`
`Genevant incorporates its General Objections as though fully set forth herein. Genevant
`
`further objects to this Request as on the basis that it does not seek information relevant to any
`
`claim or defense in this case, including because whether Roivant Sciences Ltd. is entitled to receive
`
`Litigation Proceeds is not relevant to whether any of the asserted patents are infringed or invalid,
`
`nor is it relevant to the merits vel non of Moderna’s § 1498 defense, or any other issue in this case.
`
`In re Valsartan N-Nitrosodimethylamine (NDMA) Contamination Prod. Liab. Litig., 405 F. Supp.
`
`3d 612 (D.N.J. 2019); United Access Techs., LLC v. AT&T Corp., 2020 WL 3128269, at *1 (D.
`
`Del. June 12, 2020) (finding “litigation updates provided to individuals and entities entitled to
`
`recover a portion of litigation proceeds” not relevant). Genevant further objects to this Request as
`
`vague, ambiguous, overbroad, unduly burdensome, and not proportional to the needs of the case
`
`to the extent the definition of “Litigation Proceeds” includes payments “as a result” of “a
`
`litigation,” and therefore includes payments that might indirectly result from litigation and
`
`payments that might result from litigations unrelated to this Action.
`
`FIRST SUPP. RESPONSE TO REQUEST FOR ADMISSION NO. 7 [7/28/2023]
`
`Genevant incorporates its General Objections and specific objections above as though fully
`
`set forth herein. Moderna has not identified any disputed issue on which this Request for
`
`4
`
`
`
`Case 1:22-cv-00252-MSG Document 211-15 Filed 02/02/24 Page 6 of 8 PageID #: 14490
`
`Admission is relevant, despite Genevant’s objections. Based on the parties’ meet-and-confer
`
`discussion regarding the meaning of “Litigation Proceeds,” Genevant interprets “Litigation
`
`Proceeds” to mean a right to receive a financial or monetary payment because Genevant receives
`
`proceeds from Moderna in this litigation.
`
`Subject to and without waiving the foregoing objections, Genevant
`
`
`
`
`
`
`
`
`
`5
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case 1:22-cv-00252-MSG Document 211-15 Filed 02/02/24 Page 7 of 8 PageID #: 14491
`
`
`
`
`
`
`OF COUNSEL:
`David I. Berl
`Adam D. Harber
`Thomas S. Fletcher
`Shaun P. Mahaffy
`Jessica Palmer Ryen
`Jihad J. Komis
`Anthony H. Sheh
`Philip N. Haunschild
`WILLIAMS & CONNOLLY LLP
`680 Maine Avenue S.W.
`Washington, DC 20024
`(202) 434-5000
`
`Dated: July 28, 2023
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
` Respectfully submitted,
`
`/s/ Nathan R. Hoeschen
`John W. Shaw (No. 3362)
`Karen E. Keller (No. 4489)
`Nathan R. Hoeschen (No. 6232)
`SHAW KELLER LLP
`I.M. Pei Building
`1105 North Market Street, 12th Floor
`Wilmington, DE 19801
`(302) 298-0700
`jshaw@shawkeller.com
`kkeller@shawkeller.com
`nhoeschen@shawkeller.com
`Attorneys for Plaintiff Genevant Sciences
`GmbH
`
`
`
`
`
`
`
`6
`
`
`
`Case 1:22-cv-00252-MSG Document 211-15 Filed 02/02/24 Page 8 of 8 PageID #: 14492
`
`CERTIFICATE OF SERVICE
`
`I, Nathan R. Hoeschen, hereby certify that on July 28, 2023, this document was served on
`
`the persons listed below in the manner indicated:
`
`
`
`BY EMAIL:
`Jack B. Blumenfeld
`Brian P. Egan
`MORRIS, NICHOLS, ARSHT & TUNNELL LLP
`1201 North Market Street
`P.O. Box 1347
`Wilmington, DE 19899
`(302) 658-9200
`jblumenfeld@morrisnichols.com
`began@morrisnichols.com
`
`James F. Hurst
`KIRKLAND & ELLIS LLP
`300 North LaSalle
`Chicago, IL 60654
`(312) 862-2000
`james.hurst@kirkland.com
`
`Alina Afinogenova
`KIRKLAND & ELLIS LLP
`200 Clarendon Street
`Boston, MA 02116
`(617) 385-7500
`alina.afinogenova@kirkland.com
`
`
`
`Patricia A. Carson, Ph.D.
`Jeanna M. Wacker
`Mark C. McLennan
`Nancy Kaye Horstman
`KIRKLAND & ELLIS LLP
`601 Lexington Avenue
`New York, NY 10022
`(212) 446-4800
`patricia.carson@kirkland.com
`jeanna.wacker@kirkland.com
`mark.mclennan@kirkland.com
`kaye.horstman@kirkland.com
`
`Yan-Xin Li
`KIRKLAND & ELLIS LLP
`555 California Street, 27th Floor
`San Francisco, CA 94104
`(415) 439-1400
`yanxin.li@kirkland.com
`
`
`
`
`
`/s/ Nathan R. Hoeschen
`John W. Shaw (No. 3362)
`Karen E. Keller (No. 4489)
`Nathan R. Hoeschen (No. 6232)
`SHAW KELLER LLP
`I.M. Pei Building
`1105 North Market Street, 12th Floor
`Wilmington, DE 19801
`(302) 298-0700
`jshaw@shawkeller.com
`kkeller@shawkeller.com
`nhoeschen@shawkeller.com
`Attorneys for Plaintiff Genevant Sciences
`GmbH
`
`7
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
